Article Details

Zacks: Y-mAbs Therapeutics, Inc (YMAB) Receives Average Rating of “Strong Buy” from Analysts

Retrieved on: 2019-04-05 06:52:30

Tags for this article:

Click the tags to see associated articles and topics

Zacks: Y-mAbs Therapeutics, Inc (YMAB) Receives Average Rating of “Strong Buy” from Analysts. View article details on hiswai:

Excerpt

<div>A number of institutional investors have recently added to or reduced their stakes in YMAB. <b>Sofinnova Ventures</b> Inc purchased a new stake in shares ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up